Powering what's possible
Combining Novavax’s protein-based nanoparticles with our Matrix-M® adjuvant achieves strong, long-lasting and broad immune responses.1
Protein-based Nanoparticles
Our protein-based nanoparticles are made of engineered proteins of the target pathogen used to trigger immune system recognition.2
Matrix-M® Adjuvant
Our Matrix-M adjuvant enhances the body's immune response in a targeted and efficient way, significantly improving both the magnitude and the duration of immune response.1
We are advancing a pipeline of high-value assets targeting areas with unmet medical needs, strong scientific rationale and significant commercial potential.
High-Impact Partnerships
Our strategy is to create partnership and collaboration opportunities to maximize the impact and value of our pipeline assets and Matrix-M alone.
Latest News
Keep up to date on the latest happenings at Novavax as we tackle the world’s most significant health needs.
Investors
Learn about and sign up for investor updates, including event notifications, daily stock prices, SEC filings and press releases.
- Stertman L. et al.; The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century. Hum Vaccin Immunother. 2023 Dec 31;19(1):2189885. doi: 10.1080/21645515.2023.2189885.
- Nguyen B. Tolia N; Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines. 2021 May 13;6(1):70. doi: 10.1038/s41541-021-00330-7